HIPK2 modulates p53 activity towards pro-apoptotic transcription

Molecular Cancer

Volumn 8, Issue , 2009, Pages 85-

  Puca, Rosa ^a,b   Nardinocchi, Lavinia ^a,b   Sacchi, Ada ^a   Rechavi, Gideon ^c   Givol, David ^d   D'Orazi, Gabriella ^a,b  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c SHEBA MEDICAL CENTER   (Israel)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; HOMEODOMAIN INTERACTING PROTEIN KINASE 2; LYSINE; NICOTINAMIDE; PROTEIN P300; PROTEIN P53; SERINE; SIRTUIN 1; SMALL INTERFERING RNA; TRICHOSTATIN A; ZINC CHLORIDE;

ACETYLATION; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DEACETYLATION; ENZYME INHIBITION; GENE ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO CULTURE; KNOCKOUT GENE; PROMOTER REGION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

ACETYLATION; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CARRIER PROTEINS; CELL LINE, TUMOR; DOXORUBICIN; E1A-ASSOCIATED P300 PROTEIN; GENE DELETION; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROXAMIC ACIDS; LYSINE; NIACINAMIDE; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; SIRTUIN 1; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; ZINC;

EID: 70449719002     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-85     Document Type: Article

References (43)

1. Kruse J-P, Gu W. Modes of p53 regulation. Cell 2009, 137:609-622. 10.1016/j.cell.2009.04.050, 19450511.
2. Brooks CL, Gu W. Ubiquitination, phosphorylation and acetylation: the molecular basis for p53 regulation. Curr Opin Cell Biol 2003, 15:164-171. 10.1016/S0955-0674(03)00003-6, 12648672.
3. Oda K, Arakawa H, Tanaka T, Matsuda K, Tanikawa C, Mori T, Nishimori H, Tamai K, Tokino T, Nakamura Y, Taya Y. P53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53. Cell 2000, 102:849-862. 10.1016/S0092-8674(00)00073-8, 11030628.
4. Mayo LD, Seo YR, Jackson MW, Smith ML, Rivera Guzman J, Korgaonkar CK, Donner DB. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem 2005, 280:25953-25959. 10.1074/jbc.M503026200, 15843377.
5. D'Orazi G, Cecchinelli B, Bruno T, Manni I, Higashimoto Y, Saito S, Gostissa M, Coen S, Marchetti A, Del Sal G, Piaggio G, Fanciulli M, Appella E, Soddu S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser46 and mediates apoptosis. Nature Cell Biol 2002, 4:11-19. 10.1038/ncb714, 11780126.
6. Di Stefano V, Rinaldo C, Sacchi A, Soddu S, D'Orazi G. Homeodomain-interactin protein kinase-2 activity and p53 phosphorylation are critical events for cisplatin-mediated apoptosis. Exp Cell Res 2004, 293:311-320. 10.1016/j.yexcr.2003.09.032, 14729469.
7. Pistritto G, Puca R, Nardinocchi L, Sacchi A, D'Orazi G. HIPK2-induced p53Ser46 phosphorylation activates the KILLER/DR5-mediated caspase-8 extrinsic apoptotic pathway. Cell Death Differ 2007, 10:1837-1839.
8. Kurihara A, Nagoshi H, Yabuki M, Okuyama R, Obinata M, Ikawa S. Ser46 phosphorylation of p53 is not always sufficient to induce apoptosis: multiple mechanisms of regulation of p53-dependent apoptosis. Genes to Cells 2007, 12:853-861. 10.1111/j.1365-2443.2007.01097.x, 17584297.
9. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminus domain. Cell 1997, 90:595-606. 10.1016/S0092-8674(00)80521-8, 9288740.
10. Liu L, Scolnick DM, Trievel RC, Zhang HB, Marmorstein R, Halazonetis TD, Berger SL. P53 sites acetylated in vitro by PCAF and p300 are acetylated in vivo in response to DNA damage. Mol Cell Biol 1999, 19:1202-1209. 116049, 9891054.
11. Espinosa JM, Emerson BM. Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Cell 2001, 8:57-69.
12. Barlev NA, Liu L, Chahab NH, Mansfield K, Harris KG, Halaxonetis TD, Berger SL. Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferase. Mol Cell 2001, 8:1243-1254. 10.1016/S1097-2765(01)00414-2, 11779500.
13. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW, Appella E. DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes Dev 1998, 12:2831-2841. 10.1101/gad.12.18.2831, 317174, 9744860.
14. Luo J, Su F, Chen D, Shiloh A, Gu W. Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 2000, 408:377-381. 10.1038/35042612, 11099047.
15. Hofmann TG, Moller A, Sirma H, Zentgraf H, Taya Y, Droge W, Will H, Schmitz ML. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nature Cell Biol 2002, 4:1-10. 10.1038/ncb715, 11740489.
16. Aikawa Y, Nguyen LA, Isono K, Takakura N, Tagata Y, Schmitz ML, Koseki H, Kitabayashi I. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. EMBO J 2006, 25:3955-3965. 10.1038/sj.emboj.7601273, 1560355, 16917507.
17. Luo J, Nikolaev AY, Imai S-I, Chen D, Su F, Shiloh A, Guarente L, Gu W. Negative control of p53 by Sir2α promotes cell survival under stress. Cell 2001, 107:137-148. 10.1016/S0092-8674(01)00524-4, 11672522.
18. Vaziri H, Dessain SK, Eaton EN, Imai S-I, Frye RA, Pandita TK, Guarente L, Weinberg RA. hSIR2SIRT1 functions as an NAD-dependent p53 deacetylase. Cell 2001, 107:149-159. 10.1016/S0092-8674(01)00527-X, 11672523.
19. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003, 100:10794-10799. 10.1073/pnas.1934713100, 196882, 12960381.
20. Ford J, Jiang M, Milner J. Cancer-specific functions of Sirt1 enable human specific epithelial cancer cell growth and survival. Cancer Res 2005, 65:10457-10463. 10.1158/0008-5472.CAN-05-1923, 16288037.
21. Nemoto S, Fergusson MM, Finkel T. Nutrient availability regulates Sirt1 through a fokhead-dependent pathway. Science 2004, 306:2105-2108. 10.1126/science.1101731, 15604409.
22. Puca R, Nardinocchi L, Gal H, Rechavi G, Amariglio N, Domany E, Notterman DA, Scarsella M, Leonetti C, Sacchi A, Blandino G, Givol D, D'Orazi G. Reversibile dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown. Cancer Res 2008, 68:3707-3714. 10.1158/0008-5472.CAN-07-6776, 18483253.
23. Puca R, Nardinocchi L, Bossi G, Sacchi A, Rechavi G, Givol D, D'Orazi G. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc. Exp Cell Res 2009, 315:67-75. 10.1016/j.yexcr.2008.10.018, 18996371.
24. Taira N, Nihira K, Yamaguchi T, Miki Y, Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage. Mol Cell 2007, 25:725-738. 10.1016/j.molcel.2007.02.007, 17349958.
25. Luo J, Li M, Tang Y, Laszkowska M, Roeder RG, Gu W. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci USA 2004, 101:2259-2264. 10.1073/pnas.0308762101, 356938, 14982997.
26. Zhao Y, Lu S, Wu L, Chai G, Wang H, Chen Y, Sun J, Yu Y, Zhou W, Zheng Q, Wu M, Otterson GA, Zhu WG. Acetylation of p53 at lysines 373/382 by the histone deacetylase inhibitor despipeptide induces expression of p21(Waf1/Cip1). Mol Cell Biol 2006, 7:2782-2790.
27. Knights CD, Catania J, Di Giovanni S, Muratoglu S, Perez R, Swartzbeck A, Quong AA, Zhang X, Beerman T, Pestell RG, Avantaggiati ML. Distinct p53 acetylation cassettes differentially influence gene-expression patterns and cell fate. J Cell Biol 2006, 173:533-544. 10.1083/jcb.200512059, 2063863, 16717128.
28. Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death Diff 2006, 13:951-961.
29. Britos-Bray M, Ramirez M, Cao W, Wang X, Liu PP, Civin CI, Friedman AD. CBFβ-SMMHC, expressed in M4eo acute myeloid leukaemia, reduces p53 induction and slows apoptosis in hematopoietic cells exposed to DNA-damaging agents. Blood 1998, 92:4344-4352.
30. Wee H-J, Chih-Cheng Voon D, Bae S-C, Ito Y. PEBP2-β/CBF-β-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis. Blood 2008, 112:3777-3787. 10.1182/blood-2008-01-134122, 2572802, 18695000.
31. Chen WY, Wang DW, Yen RC, Luo J, Baylin SB. Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage response. Cell 2005, 123:437-448. 10.1016/j.cell.2005.08.011, 16269335.
32. Vousden KH, Prives C. P53 and prognosis: new insight and further complexity. Cell 2005, 120:7-10.
33. Pierantoni GM, Bulfone A, Pentimalli F, Fedele M, Iuliano R, Santoro M, Chiaritoti L, Ballabio A, Fusco A. The homeodomain-interacting protein kinase 2 gene is expressed late in embryogenesis and preferentially in retina, muscle, and neural tissue. Biochem Biophys Res Commun 2002, 290:942-947. 10.1006/bbrc.2001.6310, 11798164.
34. D'Orazi G, Sciulli MG, Di Stefano V, Riccioni S, Frattini M, Falcioni R, Bertario L, Sacchi A, Patrignani P. Homeodomain-interacting protein kinase-2 restrains cytosolic phospholipase A2-dependent prostaglandin E2 generation in human colorectal cancer cells. Clin Cancer Res 2006, 12:735-741. 10.1158/1078-0432.CCR-05-1557, 16467083.
35. Li X-L, Arai Y, Harada H, Shima Y, Yoshida H, Rokudai S, Aikawa Y, Rimura A, Kitabayashi I. Mutations of the HIPK2 gene in acute myeloid leucemia and myelodysplastic sindrome impari AML1- and p53-mediated transcription. Oncogene 2007, 26:7231-7239. 10.1038/sj.onc.1210523, 17533375.
36. Pierantoni GM, Rinaldo C, Mottolese M, Di Benedetto A, Esposito F, Soddu S, Fusco A. High-mobility group A1 inhibits p53 by cytoplasmic relocalization of its proapoptotic activator HIPK2. J Clin Invest 2007, 117:93-702.
37. Rinaldo C, Prodosmo A, Mancini F, Iacovelli S, Sacchi A, Moretti F, Soddu S. MDM2-regulated degradation of HIPK2 prevents p53Ser46 phosphorylation and DNA damage-induced apoptosis. Mol Cell 2007, 2573:9-750.
38. Calzado MA, de la Vega L, Moller A, Bowtell DD, Schmitz ML. An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response. Nature Cell Biol 2009, 11:85-91. 10.1038/ncb1816, 19043406.
39. Wei G, Ku S, Ma GK, Saito S, Tang AA, Zhang J, Mao J-H, Appella E, Balmain A, Huang EJ. HIPK2 represses β-catenin-mediated transcription, epidermal stem cell expansion, and skin tumorigenesis. Proc Natl Acad Sci USA 2007, 104:13040-13045. 10.1073/pnas.0703213104, 1936219,1936219, 17666529.
40. Nardinocchi L, Puca R, Sacchi A, Rechavi G, Givol D, D'Orazi G. Targeting hypoxia in cancer cells by restoring homeodomain-interacting protein kinase 2 and p53 activity and suppressing HIF-1α. Plos ONE 2009, 4(8):e6819. 10.1371/journal.pone.0006819, 2729407, 19714248.
41. Fuster JJ, Sanz Gonzalez SM, Moll UM, Andres V. Classic and novel roles of p53: prospects for anticancer therapy. TRENDS Mol Med 2007, 13:192-199. 10.1016/j.molmed.2007.03.002, 17383232.
42. Di Stefano V, Soddu S, Sacchi A, D'Orazi G. HIPK2 contributes to PCAF-mediated p53 acetylation and selective transactivation of p21Waf1 after non-apoptotic DNA damage. Oncogene 2005, 24:5431-5442. 10.1038/sj.onc.1208717, 15897882.
43. Nardinocchi L, Puca R, Guidolin D, Belloni AS, Bossi G, Michiels C, Sacchi A, Onisto M, D'Orazi G. Transcriptional regulation of hypoxia-inducible factor 1alpha by HIPK2 suggests a novel mechanism to restrain tumor growth. Biochim Biophys Acta 2009, 1793:368-377. 10.1016/j.bbamcr.2008.10.013, 19046997.